Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemisinin add-on to risperidone in schizophrenia
NCT01391403Phase 3Completed
- Sponsor
- Peking University Huilongguan Hospital
- Start
- Sep 2008
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Artemisinin + Risperidone with Placebo + Risperidone (2 arms). Primary endpoint: Positive and Negative Syndrome Scale at 10 weeks. Started Sep 2008; status: completed.
02
Drugs
artemisinin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01391403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01391403.